SCHEMBL1808175

SCHEMBL1808175

[NH]c1cc(Cl)ccc1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL660048 0.77
SCHEMBL486558 0.74
SCHEMBL7001989 0.72
SCHEMBL1807056 0.72
SCHEMBL6943514 0.72
SCHEMBL29349499 0.71
SCHEMBL22730 0.71
SCHEMBL8873179 0.71 TP53 (1.00)
SCHEMBL11661765 0.69 TP53 (0.93)
SCHEMBL5318805 0.69 TP53 (0.93)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116019794-A Application of amino fullerene material in preparation of exosome PD-L1 inhibition drugs 中国科学院化学研究所 2023-04-28 CN claimed
EP-1607396-A1 Bicyclic inhibitors of glycogen synthase kinase 3 CHIRON CORPORATION (US) 2005-12-21 EP claimed
EP-1240168-B1 BICYCLIC INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 CHIRON CORP (US) 2005-08-31 EP claimed
US-20050080260-A1 Preparation of prodrugs for selective drug delivery LUMINIDE 2005-04-14 US claimed
US-6800632-B2 FOR TREATMENT OF DISORDERS MEDIATED BY GSK3 ACTIVITY, SUCH AS DIABETES, ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS, OBESITY, ATHEROSCLEROTIC CARDIOVASCULAR DISEASE CHIRON CORPORATION 2004-10-05 US claimed
EP-1219594-B1 New esters derived from substituted phenyl-cyclohexyl compounds VITA LAB (ES) 2004-01-14 EP claimed
US-20030100598-A1 Novel esters derived from (rr,ss)-2-hydroxybenzoate of 3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)phenyl LABORATORIOS VITA, S.A. (ES) 2003-05-29 US claimed
US-20030008866-A1 Bicyclic inhibitors of glycogen synthase kinase 3 CHIRON CORPORATION 2003-01-09 US claimed
US-6455585-B1 HAVE A HIGHER ANALGESIC ACTIVITY, A LOWER TOXICITY AND A LONGER EFFECTIVE TIME PERIOD THAN TRAMADOL. VITA INVEST, S.A. (ES) 2002-09-24 US claimed
EP-1240168-A1 BICYCLIC INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 CHIRON CORPORATION (US) 2002-09-18 EP claimed
EP-1219594-A1 New esters derived from substituted phenyl-cyclohexyl compounds VITA-INVEST, S.A. (ES) 2002-07-03 EP claimed
US-20010044436-A1 Bicyclic inhibitors of glycogen synthase kinase 3 CHIRON CORPORATION 2001-11-22 US claimed
EP-1127871-A1 NEW ESTERS DERIVED FROM SUBSTITUTED PHENYL-CYCLOHEXYL COMPOUNDS VITA-INVEST, S.A. (ES) 2001-08-29 EP claimed
WO-2001044246-A1 BICYCLIC INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 CHIRON CORPORATION (US) 2001-06-21 WO claimed
EP-1075261-A1 MYCOBACTERIAL INHIBITORS AstraZeneca AB (SE) 2001-02-14 EP claimed
WO-1999065483-A1 MYCOBACTERIAL INHIBITORS ASTRAZENECA AB (SE) 1999-12-23 WO claimed
CN-101522657-B STAT3/5 activation inhibitor OTSUKA PHARMACEUTICAL CO.,LTD. (JP) 2014-10-15 CN disclosed
EP-1957073-B1 MEDICINAL DRUG OTSUKA PHARMA CO LTD (JP) 2014-04-23 EP disclosed
US-4148805-A POLYESTERS, RED, YELLLOW CIBA-GEIGY AG (CH) 1979-04-10 US disclosed
US-4146541-A YELLOW SHADE ON POLYESTERS CIBA-GEIGY AG (CH) 1979-03-27 US disclosed